molecules of the month


CDC7 serine/threonine kinase inhibitor

oral 50 mg QD, Ph. II in solid tumors compl.

from homology model pharmacophore + opt.

Sci. Adv., May 21, 2021

Takeda Pharmaceutical, Kanagawa, JP

2 mins read

The Takeda CDC7 serine/threonine kinase inhibitor, simurosertib (TAK-931), is the first orally active CDC7-selective inhibitor and recently had its Ph. I study results in solid tumors posted. The drug was dosed as a single agent in one study at 50 mg QD with 7-day rest periods on 21-day cycles, and in another study at varying levels with varying rest schedules, suggestive of anticipated on-target tox. Neutropenia and GI adverse events appear to be drug-related (NCT02699749), and most patients did not complete the study due to progressive disease. Though the single-agent results are discouraging, the team published this paper describing their efforts to find a combination regimen and/or cancer subtype where CDC7 inhibition might be effective. Finding the right combination or right…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: